U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H22N2O3S2
Molecular Weight 390.52
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-4778574

SMILES

CC(C)S(=O)(=O)N[C@H]1CCOC[C@@H]1C2=CC=C(C=C2)C3=CC=C(S3)C#N

InChI

InChIKey=FFAGHPLLBXWCSF-MSOLQXFVSA-N
InChI=1S/C19H22N2O3S2/c1-13(2)26(22,23)21-18-9-10-24-12-17(18)14-3-5-15(6-4-14)19-8-7-16(11-20)25-19/h3-8,13,17-18,21H,9-10,12H2,1-2H3/t17-,18+/m1/s1

HIDE SMILES / InChI

Molecular Formula C19H22N2O3S2
Molecular Weight 390.52
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20347881

PF-4778574 is a potent AMPA receptor positive allosteric modulator (PAM) that has been shown to enhance cognition in animal models.Displacement studies using [3 H]PF-04725379 in rat cortical tissue determined a Ki of 85 nM for PF-4778574. The AMPAR potentiator PF-4778574 was characterized in a series of in vitro assays and acute-dose animal studies evaluating AMPAR-mediated mechanism, safety, and nootropism. Potentiator-induced animal effects were likely purely AMPAR-dependent since PF-4778574 (10 uM) only affected the dopamine transporter (IC50 of 910 nM) in a broad human-based receptor/enzyme selectivity panel.

Originator

Curator's Comment: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
45.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
American Chemical Society-239th national meeting--Investigating new therapeutic candidates: part 1. 21-25 March 2010, San Francisco, CA, USA.
2010 May
Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574.
2013 Oct

Sample Use Guides

Mice: A single dose (0.178 mg/kg) of PF-4778574 in 5:5:90 (v/v/v) DMSO:Cremophor EL:deionized H2O (0.0178 mg/ml) was administered (10 ml/kg s.c.) to CD-1 or C57BL/6J mice. Rats: Intravenous Dose. From jugular vein–cannulated Sprague-Dawley rats receiving a single bolus (1 ml/kg i.v.) of PF-4778574 (0.2 mg/kg) in 2:98 (v/v) DMSO:20% hydroxypropyl-b-cyclodextrin (0.2 mg/ml). Dogs: 0.1 mg/kg PO
Route of Administration: Other
PF-4778574 concentration-dependently increased S-AMPA–evoked responses in HEK293 cells expressing human GluA2i or GluA2o, mouse neuronal precursors, and rat primary neurons. Depending on the cell type, PF-4778574 EC50 ranged from 45 to 919 nM. PF-4778574 (10 uM) only affected the dopamine transporter (IC50 of 910 nM) in a broad human-based receptor/enzyme selectivity panel
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:53:31 GMT 2023
Edited
by admin
on Sat Dec 16 09:53:31 GMT 2023
Record UNII
TI55D82Z4B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-4778574
Common Name English
2-PROPANESULFONAMIDE, N-((3R,4S)-3-(4-(5-CYANO-2-THIENYL)PHENYL)TETRAHYDRO-2H-PYRAN-4-YL)-
Systematic Name English
PF-04778574
Common Name English
Code System Code Type Description
CAS
1219633-99-4
Created by admin on Sat Dec 16 09:53:31 GMT 2023 , Edited by admin on Sat Dec 16 09:53:31 GMT 2023
PRIMARY
PUBCHEM
44462786
Created by admin on Sat Dec 16 09:53:31 GMT 2023 , Edited by admin on Sat Dec 16 09:53:31 GMT 2023
PRIMARY
FDA UNII
TI55D82Z4B
Created by admin on Sat Dec 16 09:53:31 GMT 2023 , Edited by admin on Sat Dec 16 09:53:31 GMT 2023
PRIMARY
Related Record Type Details
TARGET->POSITIVE ALLOSTERIC MODULATOR (PAM)
Related Record Type Details
ACTIVE MOIETY